A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Clinical trial NCT04079296 · COMPLETED

Trial details

NCT number: NCT04079296
Sponsor: Astellas Pharma Global Development, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome

Start date: 2019-09-19
Primary completion: 2023-04-21
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.